Briacell Therapeutics
BCTX
16 hedge funds and large institutions have $33.5M invested in Briacell Therapeutics in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 6 closing their positions.
627% more call options, than puts
Call options by funds: $14.4M | Put options by funds: $1.98M
207% more capital invested
Capital invested by funds: $10.9M → $33.5M (+$22.6M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
13.33% more ownership
Funds ownership: 8.28% → 21.61% (+13%)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
11% less funds holding
Funds holding: 18 → 16 (-2)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KJHP
K.J. Harrison & Partners
Toronto,
Ontario, Canada
|
+$10.7M |
| 2 |
LGP
Leonard Green & Partners
Los Angeles,
California
|
+$3.94M |
| 3 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$1.93M |
| 4 |
National Bank of Canada
Montreal,
Quebec, Canada
|
+$1M |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
+$237K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Voloridge Investment Management
Jupiter,
Florida
|
-$1.48M |
| 2 |
LCM
Lynwood Capital Management
Toronto,
Ontario, Canada
|
-$276K |
| 3 |
VF
Virtu Financial
New York
|
-$207K |
| 4 |
IA
Insight Advisors
Newtown,
Pennsylvania
|
-$140K |
| 5 |
FIM
Freedom Investment Management
Hartford,
Connecticut
|
-$134K |
BCTX Hedge Fund Activity: Q1 2022 in Review
16 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Briacell Therapeutics (BCTX) for Q1 2022, worth a combined $33.5M — up 207% from $10.9M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of BCTX and 4 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 5 added.
The largest buyer was K.J. Harrison & Partners, opening a new position worth an estimated $10.7M. The largest seller was Voloridge Investment Management, cutting an estimated $1.48M.
- 16 institutional investors held Briacell Therapeutics (BCTX) as of Q1 2022, down from 18 in Q4 2021.
- Funds reported $33.5M of Briacell Therapeutics stock for Q1 2022, up 207% quarter-over-quarter.
- 4 funds opened new Briacell Therapeutics positions in Q1 2022 and 6 closed out, a net change of -2 holders.
- The largest Briacell Therapeutics buyer in Q1 2022 was K.J. Harrison & Partners, an estimated $10.7M added.
- The largest Briacell Therapeutics seller in Q1 2022 was Voloridge Investment Management, an estimated $1.48M sold.
Based on aggregated 13F filings for Q1 2022.